NEW “SynBio” Stock to Own Before the Sector Explodes

Synthetic biology firm Pfizer (PFE) may soon see a rapid rise in share value…

Year to date, shares of PFE have fallen by nearly 7.1%. This is likely due to a deceleration in COVID-19 concerns.

Even though the virus is continuing to spread, the release of vaccines has drastically reduced consumer fears. 

And reports showing the Omicron mutation is less dangerous than other variants also helped to quell COVID-19 worries.

And this, combined with the war between Russia and Ukraine, ultimately pushed pandemic-related news to the sidelines.

Still, the discovery of the “Deltacron” mutation may once again entice investors to buy shares of this synbio stock…

In recent weeks, reports have come out showing the emergence of the new strain – indicating that the virus has ultimately become an endemic issue. 

As a result, countries around the globe will likely continue to rely on PFE’s vaccines moving forward – as each new variant will require an updated version.

And that’s exactly why its booster shots received approval from the U.S. Food and Drug Administration.

It’s also the reason why PFE reported stronger-than-expected quarterly results.

On February 8, the synbio firm said its fourth-quarter earnings per share were $1.08 compared with the anticipated $0.87.

Meanwhile, PFE’s revenue was $23.84 billion – suggesting demand for its vaccines, boosters, and other treatments remain strong.

So, with COVID-19 continuing to evolve, we’ll likely see the company further develop new versions of its mRNA-based vaccine on an annual basis. And as this happens, synbio firms such as PFE could benefit from consistent demand for updated vaccines.

Do you know Steve Jobs' “Final Prophecy?”

Sponsored

In his biography, just before he died, Apple founder Steve Jobs issued a “Final Prophecy.”

This was back in 2011.

At the time, Jobs' prediction didn't get much attention – in fact, I think few actually understood what he meant.

But today, with so many digital technology stocks crashing all around us, it's becoming more and more clear that Steve Jobs' “Final Prophecy” is coming to life RIGHT NOW.

Keep in mind, this was the guy who accurately predicted the Internet, laptop computers, Siri and Alexa voice assistants, e-commerce, and cloud computing, just to name a few… long before these things were a blip on the radar.

As Walter Isaacson, Jobs' biographer, says:

And that's exactly why today I want to tell you about Steve Jobs' “Final Prophecy” – because it is coming to life right now… And more importantly, I believe it will result in by far the biggest investment gains in the world over the next decade.

So… for the next few minutes… forget the technologies dominating today's headlines…

Forget cryptocurrencies, 5G, electric vehicles, and self-driving cars. Forget the blockchain, quantum computing, artificial intelligence, and virtual reality. Forget NFTs, apps, space exploration, and cloud computing.

I want to show you something totally new and radically different.

I think you're going to be blown away by this – it truly is incredible.

All the details are in my brand-new presentation, which I just posted on my company's website. You can access it totally free of charge, right here

P.S. I almost forgot to tell you…

In my new presentation I also reveal my #1 favorite stock to take advantage of Steve Jobs' “Final Prophecy,” right now. It's an incredible business I think you can probably buy and hold for the next decade or more. The profit potential is enormous. No e-mail, subscription, or credit card required to get my #1 pick.

$2 EV Stock No One's Talking About

This company is a sneaky EV play that no one’s talking about. They’re producing an odd variation on the traditional EV that has consumers raving.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$30 Stock Freaking Out Billionaires

This stock is an industry leader in a robotics technology that is freaking out billionaires (trading for just $30).

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

The Best TaaS Stock Right Now

This company is set to corner the market in a self-driving technology that  could fundamentally change our entire society – much like the internet did.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Up to 20,000 IPOs All in One Day

A radical $2.1 quadrillion shift is coming to the financial markets.

Some are calling it G.T.E. and Mark Cuban, Elon Musk, Richard Branson, and even banks like J.P. Morgan are invested in the tech behind it.

Just $25 could get you in alongside these billionaires. 

Enter your email address to receive the video that reveals it all.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

53-cent Biotech Stock with $2 Price Target

Steve Cohen, the billionaire stock picker known for running one of the most successful hedge funds ever, has poured millions into the first stock, and it’s trading for only 53 cents.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works